Cullinan Oncology Stock (NASDAQ:CGEM)
Previous Close
$9.53
52W Range
$9.06 - $30.19
50D Avg
$11.22
200D Avg
$16.68
Market Cap
$539.19M
Avg Vol (3M)
$523.96K
Beta
-0.16
Div Yield
-
CGEM Company Profile
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
CGEM Performance
Latest News
Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC
Jan 09, 25 | 11:11 PM | seekingalpha.comCullinan Therapeutics: Casting A Wide Net With Their Pipeline
Jan 08, 25 | 5:26 PM | seekingalpha.comCullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
Nov 14, 24 | 10:01 AM | globenewswire.comCullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
Nov 05, 24 | 7:00 AM | globenewswire.comCullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
Nov 04, 24 | 7:00 AM | globenewswire.comCullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
Sep 17, 24 | 7:00 AM | globenewswire.comCullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
Sep 14, 24 | 4:15 AM | globenewswire.comCullinan Therapeutics to Participate in Upcoming Investor Conferences
Aug 28, 24 | 8:00 AM | globenewswire.comCullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Jun 01, 24 | 7:00 AM | globenewswire.comCullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
May 24, 24 | 8:00 AM | globenewswire.comCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 15, 24 | 4:05 PM | globenewswire.comCullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Apr 29, 24 | 7:00 AM | globenewswire.comCullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Apr 16, 24 | 7:00 AM | globenewswire.comCullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Apr 16, 24 | 6:59 AM | globenewswire.comCullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Mar 14, 24 | 7:00 AM | globenewswire.comCullinan Oncology to Participate in Upcoming Investor Conferences
Feb 27, 24 | 8:00 AM | globenewswire.comCullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Dec 18, 23 | 4:53 PM | globenewswire.comCullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
Dec 14, 23 | 4:30 PM | globenewswire.comCullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Nov 08, 23 | 7:00 AM | globenewswire.comCullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
Nov 03, 23 | 12:01 PM | globenewswire.comLatest Sec Filing
Peer Comparison
Ticker | Company |
---|---|
MLYS | Mineralys Therapeutics, Inc. |
RVMD | Revolution Medicines, Inc. |
CCCC | C4 Therapeutics, Inc. |
IPSC | Century Therapeutics, Inc. |
ZNTL | Zentalis Pharmaceuticals, Inc. |
AUTL | Autolus Therapeutics plc |
BOLT | Bolt Biotherapeutics, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
LYRA | Lyra Therapeutics, Inc. |
SANA | Sana Biotechnology, Inc. |
LYEL | Lyell Immunopharma, Inc. |
GLUE | Monte Rosa Therapeutics, Inc. |
OLMA | Olema Pharmaceuticals, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
VOR | Vor Biopharma Inc. |
ACET | Adicet Bio, Inc. |
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools